hydroxyurea has been researched along with Osteogenic Sarcoma in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Osteosarcoma cells were treated with hydroxyurea to investigate the expression pattern of TET proteins in these cells." | 7.91 | Hydroxyurea promotes TET1 expression and induces apoptosis in osteosarcoma cells. ( Ma, C; Teng, S; Yi, C; Yu, Y, 2019) |
| " Osteosarcoma cells were treated with hydroxyurea to investigate the expression pattern of TET proteins in these cells." | 3.91 | Hydroxyurea promotes TET1 expression and induces apoptosis in osteosarcoma cells. ( Ma, C; Teng, S; Yi, C; Yu, Y, 2019) |
| " Furthermore, the non-cytolytic and non-cytotoxic metronomic hydroxyurea dosage increased the biological therapy outcome by strengthening antitumor capability." | 1.72 | A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness. ( Borghetto, V; Costanzo, E; Di Bella, G; Di Bella, L; Moscato, I, 2022) |
| "Bloom Syndrome is an autosomal recessive cancer-prone disorder caused by mutations in the BLM gene." | 1.35 | BLAP18/RMI2, a novel OB-fold-containing protein, is an essential component of the Bloom helicase-double Holliday junction dissolvasome. ( Ali, AM; Andreassen, PR; Busygina, V; Du, CH; Fan, Q; Meetei, AR; Raynard, S; Singh, TR; Sung, P, 2008) |
| "Hydroxyurea treatment of proliferating osteoblasts blocked PROM-1 expression; however, its expression was not cell cycle regulated." | 1.30 | Detection of a proliferation specific gene during development of the osteoblast phenotype by mRNA differential display. ( Lian, JB; Ryoo, HM; Stein, GS; Stein, JL; van Wijnen, AJ, 1997) |
| "Hydroxyurea treatment was used to inhibit DNA synthesis and produce growth arrest in osteoblastic cells." | 1.30 | p53 transactivity during in vitro osteoblast differentiation in a rat osteosarcoma cell line. ( Campione, AL; Chandar, N; Lanciloti, NJ; Moore, MK; Schwartz, KA, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Di Bella, G | 1 |
| Di Bella, L | 1 |
| Borghetto, V | 1 |
| Moscato, I | 1 |
| Costanzo, E | 1 |
| Campbell, AE | 1 |
| Ferraz Franco, C | 1 |
| Su, LI | 1 |
| Corbin, EK | 1 |
| Perkins, S | 1 |
| Kalyuzhnyy, A | 1 |
| Jones, AR | 1 |
| Brownridge, PJ | 1 |
| Perkins, ND | 1 |
| Eyers, CE | 1 |
| Teng, S | 1 |
| Ma, C | 1 |
| Yu, Y | 1 |
| Yi, C | 1 |
| Singh, TR | 1 |
| Ali, AM | 1 |
| Busygina, V | 1 |
| Raynard, S | 1 |
| Fan, Q | 1 |
| Du, CH | 1 |
| Andreassen, PR | 1 |
| Sung, P | 1 |
| Meetei, AR | 1 |
| Mao, FJ | 1 |
| Sidorova, JM | 1 |
| Lauper, JM | 1 |
| Emond, MJ | 1 |
| Monnat, RJ | 1 |
| Johnson, M | 1 |
| Sharma, M | 1 |
| Brocardo, MG | 1 |
| Henderson, BR | 1 |
| FERNBACH, DJ | 2 |
| Duensing, A | 1 |
| Liu, Y | 1 |
| Spardy, N | 1 |
| Bartoli, K | 1 |
| Tseng, M | 1 |
| Kwon, JA | 1 |
| Teng, X | 1 |
| Duensing, S | 1 |
| Nayab, SN | 1 |
| Jones, FH | 1 |
| Olsen, I | 1 |
| Kim, JM | 1 |
| Kakusho, N | 1 |
| Yamada, M | 1 |
| Kanoh, Y | 1 |
| Takemoto, N | 1 |
| Masai, H | 1 |
| Kockx, M | 1 |
| McCabe, L | 1 |
| Stein, JL | 2 |
| Lian, JB | 2 |
| Stein, GS | 2 |
| Ryoo, HM | 1 |
| van Wijnen, AJ | 1 |
| van Oijen, MG | 1 |
| Medema, RH | 1 |
| Slootweg, PJ | 1 |
| Rijksen, G | 1 |
| Schwartz, KA | 1 |
| Lanciloti, NJ | 1 |
| Moore, MK | 1 |
| Campione, AL | 1 |
| Chandar, N | 1 |
| Goodrich, DW | 1 |
| Wang, NP | 1 |
| Qian, YW | 1 |
| Lee, EY | 1 |
| Lee, WH | 1 |
| Griswold, DP | 1 |
| Dykes, DJ | 1 |
| Kelley, CA | 1 |
| Roberts, BJ | 1 |
| Dominick, CA | 1 |
| Sugiura, K | 1 |
| Sutow, WW | 1 |
| Vietti, TJ | 1 |
| Lane, DM | 1 |
| Donaldson, MH | 1 |
| Lonsdale, D | 1 |
18 other studies available for hydroxyurea and Osteogenic Sarcoma
| Article | Year |
|---|---|
A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness.
Topics: Antioxidants; Bone Neoplasms; Butyric Acid; Humans; Hydroxyurea; Melatonin; Osteosarcoma; Tretinoin | 2022 |
Temporal modulation of the NF-κB RelA network in response to different types of DNA damage.
Topics: Amino Acid Motifs; Amino Acid Sequence; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Chromatography, | 2021 |
Hydroxyurea promotes TET1 expression and induces apoptosis in osteosarcoma cells.
Topics: 5-Methylcytosine; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Ce | 2019 |
BLAP18/RMI2, a novel OB-fold-containing protein, is an essential component of the Bloom helicase-double Holliday junction dissolvasome.
Topics: Amino Acid Sequence; Animals; Bloom Syndrome; Bone Neoplasms; Carrier Proteins; Cell Nucleus; Cells, | 2008 |
The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage.
Topics: Antineoplastic Agents; Bone Neoplasms; Bromodeoxyuridine; Camptothecin; Cell Growth Processes; Cell | 2010 |
IQGAP1 translocates to the nucleus in early S-phase and contributes to cell cycle progression after DNA replication arrest.
Topics: Active Transport, Cell Nucleus; Animals; Cell Line, Tumor; Cell Nucleus; Cytoplasm; DNA Replication; | 2011 |
PEDIATRIC CLINICAL TRIALS WITH HYDROXYUREA (NSC-32065).
Topics: Adolescent; Antineoplastic Agents; Child; Drug Therapy; Hodgkin Disease; Hydroxyurea; Leukemia; Neop | 1964 |
RNA polymerase II transcription is required for human papillomavirus type 16 E7- and hydroxyurea-induced centriole overduplication.
Topics: Amanitins; Bone Neoplasms; Centrosome; CREB-Binding Protein; Cyclin A; Cyclin A2; Enzyme Inhibitors; | 2007 |
Modulation of the human bone cell cycle by calcium ion-implantation of titanium.
Topics: Adolescent; Calcium; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytoprotection; Demecolcine; | 2007 |
Cdc7 kinase mediates Claspin phosphorylation in DNA replication checkpoint.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated | 2008 |
Influence of DNA replication inhibition on expression of cell growth and tissue-specific genes in osteoblasts and osteosarcoma cells.
Topics: Alkaline Phosphatase; Animals; Cell Cycle; Cell Differentiation; Cell Division; Collagen; DNA; DNA R | 1994 |
Detection of a proliferation specific gene during development of the osteoblast phenotype by mRNA differential display.
Topics: Amino Acid Sequence; Animals; Base Sequence; Biomarkers; Blotting, Northern; Calcitriol; Cell Differ | 1997 |
Positivity of the proliferation marker Ki-67 in noncycling cells.
Topics: Antineoplastic Agents; Biomarkers; Bone Neoplasms; Cell Count; Cell Division; Cyclin-Dependent Kinas | 1998 |
p53 transactivity during in vitro osteoblast differentiation in a rat osteosarcoma cell line.
Topics: Animals; Biomarkers; Cell Cycle; Cell Differentiation; Chloramphenicol O-Acetyltransferase; Cholecal | 1999 |
The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle.
Topics: Animals; Antigens, Viral; Aphidicolin; Baculoviridae; Bromodeoxyuridine; Cell Line; Electrophoresis, | 1991 |
Approaches to combination chemotherapy in rat, mouse, and hamster tumors.
Topics: Adenocarcinoma; Amides; Androstanols; Animals; Antineoplastic Agents; Cricetinae; Cyclohexanes; Cycl | 1974 |
Effect of 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962) and two related compounds on a spectrum of tumors.
Topics: Adenocarcinoma; Animals; Carcinoma, Ehrlich Tumor; Carcinoma, Krebs 2; Fibrosarcoma; Glioma; Hydroxy | 1967 |
Evaluation of chemotherapy in children with metastatic Ewing's sarcoma and osteogenic sarcoma.
Topics: Adolescent; Amines; Antineoplastic Agents; Child; Child, Preschool; Cyclophosphamide; Daunorubicin; | 1971 |